COMP <GO>
ANIP vs RARE // REVENUE GROWTH (YOY)
ANI Pharmaceuticals Inc. (NASDAQ) VS. Ultragenyx Pharmaceutical Inc. (NASDAQ) • 15-METRIC TALLY: ANIP 8
— RARE 1
▲ REVENUE GROWTH (YOY) LEADER: ANIP
LAST: $73.16 (+2.02%) • MKT CAP: $1.68B
revenue-growth
43.80%
LAST: $16.78 (-2.44%) • MKT CAP: $1.65B
revenue-growth
20.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANIP VS. RARE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANIP | RARE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | -35.00% | +51.00 | ANIP | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.7x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 10.20% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 12.60% | -60.00% | +72.60 | ANIP | /operating-margins <GO> |
| Net Profit Margin | 8.80% | -60.00% | +68.80 | ANIP | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 43.80% | 20.20% | +23.60 | ANIP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.07% | 0.00% | +0.07 | ANIP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.36 | 0.20 | +2.16 | ANIP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 3/9 | +5.00 | ANIP | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.2 | 49.8 | -2.65 | RARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.1x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.68B | $1.65B | $25.4M | ANIP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANIP REV | RARE REV | ANIP GROSS % | RARE GROSS % | ANIP FCF | RARE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $883.4M | $673.0M | — | — | $171.4M | -$472.0M |
| FY 2024 | $614.4M | $560.0M | — | — | $47.8M | -$421.0M |
| FY 2023 | $486.8M | $434.0M | — | — | $119.0M | -$475.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANIP // BETA —
RARE // BETA —